Turoctocog alfa: Difference between revisions
CSV import |
No edit summary |
||
| Line 28: | Line 28: | ||
[[Category:Factor VIII]] | [[Category:Factor VIII]] | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 17:43, 18 March 2025
Turoctocog alfa (trade name NovoEight) is a recombinant form of human Factor VIII, a protein that is necessary for normal blood clotting. It is used to treat and prevent bleeding in people with Hemophilia A. Turoctocog alfa is produced by recombinant DNA technology in Chinese hamster ovary cells.
Etymology[edit]
The name "Turoctocog alfa" is derived from the Latin "turocto", meaning "to turn", and "cog", meaning "together". The "alfa" indicates that it is the first version of this medication.
Medical Uses[edit]
Turoctocog alfa is used to treat and prevent bleeding in people with Hemophilia A. It is not used to treat Hemophilia B, which involves a different clotting factor. Turoctocog alfa is given by injection into a vein.
Side Effects[edit]
Common side effects of Turoctocog alfa include headache, fever, and reactions at the injection site. Serious side effects may include allergic reactions and the development of antibodies against Factor VIII.
Pharmacology[edit]
Turoctocog alfa works by replacing the missing Factor VIII, a clotting factor that is necessary for normal blood clotting. It is a recombinant form of human Factor VIII, meaning it is produced by genetically engineered cells.
History[edit]
Turoctocog alfa was approved for medical use in the United States in 2013. It is marketed under the trade name NovoEight by Novo Nordisk.
See Also[edit]
References[edit]
<references />
